Peptides for aesthetic clinics: adding a line, not starting a business.

The economics only work because you already have the expensive parts

The practices that make this work are not treating it as a new venture. They are adding a line to one that already exists.

Consider what a standalone peptide business actually needs. Premises someone will walk into. A booking system. A client base that trusts you enough to say yes to something unfamiliar. Staff who can handle stock properly. Cold storage. A reason for anyone to be in the building at all. A med spa or aesthetic clinic has every one of those already, paid for, running, and currently in use for something else six days a week.

The marginal cost of adding a research compound line to that is stock and a shelf. Everything else is already a sunk cost being amortised over the existing service menu.

Customer acquisition is the number that changes

A standalone reseller pays to acquire a customer on every order. That cost sits underneath every transaction and it does not go away with scale.

A practice is not acquiring anyone. It is adding a line to a conversation it was already having, with a client who is already in the chair, who booked for a different reason and is already paying for something. The marginal acquisition cost is close to zero.

That single difference is why the arithmetic looks so unlike a reseller's from the inside, and it is why practices tend to underestimate the opportunity: they benchmark against what a reseller makes per vial rather than against what the same appointment slot was earning before.

The constraint is supply reliability, not demand

This is where most practices get caught, and it is worth being blunt about.

A service menu item that is available in March and unavailable in April is worse than one you never offered. The one you never offered cost you nothing. The one that vanished cost you a client's confidence in the rest of the menu, because a client who was told something was available and then told it was not now has a reason to wonder what else might not be there.

Once a treatment is on the menu, the supply behind it has to be as dependable as the room and the appointment slot. A practice sourcing from an overseas shipment measured in weeks structurally cannot promise that, however good the unit price is. This is the entire argument for local stock in a practice setting: not that the vial is cheaper, but that the line on your menu stays true.

A restock measured in hours means you can put something on the menu and keep it there. A restock measured in weeks means periodically taking it off, and that is the thing that actually costs money.

Which compounds practices ask about

Three of the seventeen in the catalogue come up in aesthetic and dermatology contexts more than the rest. Described here by what they are, which is the only way this page will describe them.

GHK-Cu is a copper tripeptide complex, a short peptide bound to copper, supplied as a 50mg lyophilised vial. It is the compound most associated with topical and cosmetic formulation research. The blue colour in the vial is the copper itself rather than any added dye.

GLOW Blend is a co-lyophilised 70mg blend and KLOW Blend an 80mg one. Both combine several peptides in a single vial rather than requiring separate vials reconstituted individually. That is usually why practices ask about them: one item to store, one to record, one to handle.

What none of those descriptions contains is an indication, an outcome, a protocol or a dose. That is deliberate and it is not coyness. See the section on the regulatory position below.

How supply slots into a practice that already runs

You already have an inventory process. This is about fitting into it rather than replacing it.

Every vial carries a batch number, which is what makes it recordable in whatever system you already use. If you log lot numbers against a treatment record, you can do it here the same way. Nobody is asking you to adopt a portal.

The useful restock cadence for most practices is a standing order sized to a month with a top-up route for a busy week, rather than reordering reactively each time something runs low. Reactive reordering is how a practice ends up permanently a week behind its own appointment book. Once a supplier knows your cadence, stock is held against it and the reorder becomes a message rather than a scramble.

The full operational detail is on clinic and med spa supply.

Cold storage in a clinic setting

Sealed lyophilised powder is stable in a freezer and tolerates a fridge. Once reconstituted, a vial belongs in the fridge and should not be frozen.

In a practice the harder constraint is usually traffic rather than temperature. A treatment room fridge opened dozens of times a day cycles its internal temperature constantly, and the stock inside rides every one of those cycles even though the set temperature reads the same as a dedicated unit. A small separate fridge for stock is worth more than a larger shared one, and it is inexpensive.

Fuller detail on holding inventory in Philippine conditions, including power interruption, is in storing peptide stock in the Philippines.

What arrives with the order

Bacteriostatic water, insulin syringes, alcohol prep pads, a reconstitution syringe and blank labels, in the box, scaled to the order and included rather than charged separately.

For a practice the value is not the consumables. It is that the order arrives complete and does not generate a second procurement task on a different lead time from a different supplier. Nobody discovers on the day that the water arrived and the syringes did not.

Consumables also tend to be the line that falls through the gap between whoever orders stock and whoever uses it. Arriving together and in proportion means the two cannot get out of step. Contents are on what ships in the box.

The regulatory position, stated plainly

Nothing in this catalogue is an approved medicine in the Philippines. No regulator has cleared any of it for a therapeutic use, none of it is registered with the FDA here, and all of it is supplied for research use only.

A practice that administers any of it is making its own regulatory decision and carrying its own exposure. That is not a disclaimer at the bottom of a page, it is the actual position, and a supplier who softens it is telling you what you want to hear rather than what is true.

It follows that no protocols, dosing guidance or treatment claims are supplied, and none will be. Not out of modesty, but because the line between supplying a research chemical and practising medicine through someone else's clinic is exactly there. Any supplier offering a clinic a ready-made protocol and a set of claims to repeat is handing over a liability along with the vial.

If your plan depends on being given clinical material to work from, this is worth knowing in the first message rather than the fifth.

Where to start

Every price we publish sits on the pack pricing page, including the deepest tier, open to anyone with no conversation. For a practice testing whether a line works at all, that is the right place to begin: buy a pack, see whether it moves, and find out what your own book actually does with it.

An account becomes worth it later, when volume is genuinely above a pack or when running out is the thing that would cost you most. Starting with an account before you know your run rate means guessing at an allocation, and a guessed allocation is wrong in one direction or the other.